A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Project: Research

Project Description

NMA Reference Number: HREC/16/MonH/50
NMA SSA Reference: SSA/16/MonH/101
Monash Health HREC Ref: 16150A
StatusActive
Effective start/end date30/08/19 → 29/08/24
View all
View less

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • blood cancers